PLUR Pluri Inc.
Listings ·
Nasdaq confirmed the matter is closed after Pluri elected Eitan Ajchenbaum as an independent director and Audit Committee chair. The gap began after the June 30, 2025 annual meeting.
Pluri told Nasdaq it fell below the three-independent-director minimum for its audit committee after shareholders voted against director Doron Birger, who chaired it. The cure period ends no later than June 30, 2026, and the company says it will add an independent director.
The investor is a company wholly beneficially owned by director Alejandro Weinstein. The new warrants can be exercised only after shareholder approvals required by Nasdaq rules.
Nasdaq accepted Pluri's compliance plan after a November 25, 2024 deficiency letter. The company must show $2,500,000 in stockholders' equity by the deadline or may face delisting, and its shares keep trading as PLUR.
Pluri Inc. is a biotechnology company built on a proprietary 3D cell expansion platform and an in-house, industrial-scale cell manufacturing facility. The platform supports two application areas: Human Health and Longevity, and Foodtech and Bio-Farming. In human health, the company develops placenta-derived cell therapy candidates. PLX-PAD is composed of maternal mesenchymal stromal cell-like cells and has been tested for acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, graft versus host disease and peripheral artery disease. It is also being developed for mild to moderate knee osteoarthritis as part of the PROTO program led by Charité Berlin Institute of Health Center for Regenerative Therapies. PLX-R18 was tested in a Phase I trial for incomplete recovery following hematopoietic cell transplantation. The company's allogeneic placental MAIT cell platform targets solid tumors. Partners named in the text include Bar-Ilan University's commercial arm BIRAD, which holds rights to develop PLX cells as a cocaine anti-addiction product, and Hemafund, a Ukrainian umbilical cord blood bank, whose collaboration on PLX-R18 is not currently active.
| Product or program | What it is | Stage |
|---|---|---|
| PLX-PAD | Placenta-derived adherent stromal cells for several indications, including knee osteoarthritis | Clinical study approved by Germany's PEI in June 2025 |
| PLX-R18 | Fetal MSC-like placenta-derived cells for incomplete recovery after transplantation and acute radiation syndrome | Tested in a Phase I trial |
| Placental MAIT cell immunotherapy | Allogeneic immunotherapy platform for solid tumors | Platform launched in May 2024 |
| PluriCDMO | Development and manufacturing services for cell-based products | Offered |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Revenue | $1.0 million | $1.3 million |
| Research and development | $15.1 million | $12.9 million |
| Net income (loss) | -$23.8 million | -$22.6 million |
| Cash from operations | -$19.6 million | -$18.2 million |
| Cash and equivalents | $3.5 million | $5.9 million |
Our latest story on this, dated Jan 21, 2025: "Pluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 21, 2025: "Pluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance". The story links the filing or release it is based on. Read the story.
Pluri Inc. trades under the ticker PLUR on NASDAQ.
Pluri Inc. is listed on NASDAQ. Our directory also records these other listings: TASE:PLUR.
The SEC Central Index Key (CIK) for Pluri Inc. is 1158780. Its filings are on SEC EDGAR.
12,344,736 shares as of 2026-09-09, per the cover page of its 10-K filed 2026-09-10.
Our directory records Pluri Inc. under Israel.
Our directory classifies Pluri Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Pluri Inc. is US72942G2030.
aibio.space lists Pluri Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Pluri Inc. is a biotechnology company built on a proprietary 3D cell expansion platform and an in-house, industrial-scale cell manufacturing facility. The platform supports two application areas: Human Health and Longevity, and Foodtech and Bio-Farming.
PLX-PAD: Placenta-derived adherent stromal cells for several indications, including knee osteoarthritis Stage: Clinical study approved by Germany's PEI in June 2025.
PLX-R18: Fetal MSC-like placenta-derived cells for incomplete recovery after transplantation and acute radiation syndrome Stage: Tested in a Phase I trial.
$1.0 million for the fiscal year ended Jun 30, 2026, as reported to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio